Wire · opportunities
Moderna's mRNA Flu Vaccine Wins FDA Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 August 2026 · Fusion42 review
The FDA has approved Moderna's first mRNA-based seasonal flu vaccine, mFLUSIVA, for adults aged 50 and older following a unanimous advisory committee vote and clinical trials involving around 44,000 participants. The vaccine will be available in the US for the 2026-2027 flu season and is also under review in the EU, Canada, and Australia.
This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 6 Aug 2026 and 27 Aug 2026.
◆ ◆ The Wire takeaway
Your biotech ventures must now factor mRNA flu vaccines as a dominant modality in respiratory disease treatment and prevention. The proven FDA path and large-scale trial success clear a strong route to market entry for new mRNA products focused on older adults.
◆ Coverage
12 sources · first reported 6 Aug 2026 · latest 27 Aug 2026
◆ Related on Wire
◆ Topics